Department of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, People's Republic of China.
Support Care Cancer. 2012 Aug;20(8):1815-22. doi: 10.1007/s00520-011-1280-z. Epub 2011 Oct 5.
A number of studies have reported that aprepitant has been used to prevent chemotherapy-induced nausea and vomiting. In this study, we aimed to analyze the efficacy and safety of aprepitant, which can provide evidence for aprepitant administration.
Fifteen trials involving patients who received moderately or highly emetogenic chemotherapy were included in this pooled analysis. Antiemetic drugs in these studies included aprepitant, dexamethasone, and 5-HT3 receptor antagonists.
A total of 4,798 cases were investigated in these clinical trials. Compared with placebo or the standard antiemetic therapy, the cumulative incidence of emesis was significantly reduced in the patients treated with aprepitant-based (125 mg/80 mg) therapy on the first day [relative risk (RR) = 1.13, 95% confidence interval (CI) 1.10-1.16], from 2 to 5 days (RR = 1.35, 95% CI 1.22-1.48) and in the overall 5 days (RR = 1.30, 95% CI 1.22-1.39). In terms of drug safety, there was no significant difference between aprepitant-based regimens and non-aprepitant regimens.
Results from the analysis suggest that aprepitant with 5-HT3 receptor antagonists and dexamethasone is highly effective in preventing nausea and vomiting in the days after administration of moderately or highly emetogenic chemotherapy (MEC or HEC) agents.
多项研究报告称，阿瑞匹坦已被用于预防化疗引起的恶心和呕吐。本研究旨在分析阿瑞匹坦的疗效和安全性，为阿瑞匹坦的应用提供依据。
本荟萃分析纳入了 15 项涉及接受中度或高度致吐性化疗的患者的试验。这些研究中的止吐药物包括阿瑞匹坦、地塞米松和 5-HT3 受体拮抗剂。
这些临床试验共纳入 4798 例。与安慰剂或标准止吐治疗相比，阿瑞匹坦（125mg/80mg）治疗组第 1 天[相对风险（RR）=1.13，95%置信区间（CI）1.10-1.16]、第 2-5 天（RR=1.35，95%CI 1.22-1.48）和总 5 天（RR=1.30，95%CI 1.22-1.39）的呕吐累积发生率显著降低。在药物安全性方面，阿瑞匹坦方案与非阿瑞匹坦方案之间无显著差异。
分析结果表明，阿瑞匹坦联合 5-HT3 受体拮抗剂和地塞米松在预防中度或高度致吐性化疗（MEC 或 HEC）药物后数天内的恶心和呕吐方面非常有效。
